Answers are grounded in this paper and cite their sources.
Qualitative study explores barriers in using generic medicines for Type 2 Diabetes in Mysuru, suggesting pathways for improvement.
Despite policy efforts to promote Jan Aushadhi medicines (JAM) in India, their utilization for chronic disease management remains limited, particularly among patients with Type 2 Diabetes Mellitus (T2DM). Understanding stakeholder perceptions is critical to improving acceptance and uptake. A qualitative descriptive study was conducted in Mysuru Taluka, Karnataka. A total of 29 participants, including T2DM patients, public and private healthcare providers, pharmacists, and Auxiliary Nurse Midwives, were recruited using purposive sampling. Data were collected through in-depth interviews and a focus group discussion and analyzed using inductive thematic analysis supported by NVivo software. Private healthcare providers and branded-medicine users expressed skepticism regarding JAM quality and efficacy, while public providers and ASHAs emphasized affordability but reported mistrust and inconsistent availability. Limited provider endorsement emerged as a key barrier influencing patient medicine choices. The study highlights that perceptions of quality, provider influence, and system-level constraints shape JAM utilization among T2DM patients. Addressing these barriers through targeted provider engagement and patient-focused communication strategies may enhance acceptance of JAM.
No takes yet. Share an insight, caveat, or question.
Sulochanadevi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: